IRVINE, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate in two upcoming investor conferences in September. The first conference is the 2013 Stifel Healthcare Conference in Boston.
|Event: Stifel 2013 Healthcare Conference|
|Date: Thursday, September 12, 2013|
|Time: 3:15 p.m. ET / 12:15 p.m. PT|
|Endologix Participant: Shelley Thunen (CFO)|
The second conference is the 4th Annual Credit Suisse Small/Mid Cap Conference in New York. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.
|Event: 4th Annual Credit Suisse Small/Mid Cap Conference|
|Date: Tuesday, September 17, 2013|
|Endologix Participant: John McDermott (President & CEO)|
An audio webcast of the Company's presentation at the Stifel 2013 Healthcare Conference will be available by visiting the investor relations section of Endologix's website at www.endologix.com. A replay of the presentation will be available for 30 days.
About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. Endologix focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.
CONTACT: COMPANY CONTACT: Endologix, Inc. John McDermott, CEO Shelley Thunen, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico (646) 536-7030 Zack Kubow (646) 536-7020Source:Endologix